Jack A. Khattar - 20 Dec 2022 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role
President, CEO, Director
Signature
/s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol
SUPN
Transactions as of
20 Dec 2022
Transactions value $
-$346,387
Form type
4
Filing time
22 Dec 2022, 16:00:56 UTC
Previous filing
28 Nov 2022
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SUPN Common Stock Options Exercise $62,407 +6,528 +0.83% $9.56 795,962 20 Dec 2022 Direct F1
transaction SUPN Common Stock Sale -$152,316 -4,006 -0.5% $38.02 791,956 20 Dec 2022 Direct F1, F2
transaction SUPN Common Stock Award $0 +15,625 +1.97% $0 807,581 21 Dec 2022 Direct F3
transaction SUPN Common Stock Options Exercise $176,592 +18,472 +2.29% $9.56 826,053 21 Dec 2022 Direct F1
transaction SUPN Common Stock Sale -$433,069 -11,354 -1.37% $38.14 814,699 21 Dec 2022 Direct F1, F4
holding SUPN Common Stock 1,047,700 20 Dec 2022 By the KBT Trust F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -6,528 -5.22% $0 118,472 20 Dec 2022 Common Stock 6,528 $9.56 Direct F1, F6
transaction SUPN Employee Stock Option (Right to Buy) Options Exercise $0 -18,472 -15.59% $0 100,000 20 Dec 2022 Common Stock 18,472 $9.56 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.09, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 21, 2020.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.38, inclusive. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5 The Reporting Person is no longer required to report shares held by his son as he no longer shares the Reporting Person's household.
F6 The options vested in four equal annual installments beginning on January 23, 2015.